Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 5Completed 3Terminated 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 8Gastrointestinal 4CNS 4Sarcoma 3Head & Neck 3Thoracic 2Gynecologic 2Dermatologic 2Tumor-Agnostic 1Lymphoid 1Genitourinary 1Endocrine 1

Conditions

Stomach Neoplasms 1Ovarian Neoplasms 1Endometrial Neoplasms 1Carcinosarcoma 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × ribociclib × Gynecologic × Clear all
NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
33 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡